Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth P Lerner

Showing results (201-210 of 294) with videos related to

Pageof 30
Sort By:
BJU International|May 6, 2008
Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control studyJochen Walz, Shahrokh F Shariat, Nazareno Suardi, et al.
World Journal of Urology|September 9, 2016
Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)Francesco Soria, Shahrokh F Shariat, Seth P Lerner, et al.
The Journal of Urology|November 17, 2009
Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancerShahrokh F Shariat, Daher C Chade, Pierre I Karakiewicz, et al.
Journal of Oncology Practice|August 11, 2017
Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline SummarySam S Chang, Bernard H Bochner, Roger Chou, et al.
The Journal of Urology|May 1, 2017
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO GuidelineSam S Chang, Bernard H Bochner, Roger Chou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2022
Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative GroupsHeiko Schöder, Thomas A Hope, Michael Knopp, et al.
Future Oncology (London, England)|May 24, 2022
Targeting <i>FGFR3</i> alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trialSumanta K Pal, Diederik M Somford, Petros Grivas, et al.
BJU International|August 8, 2009
p53 expression in patients with advanced urothelial cancer of the urinary bladderShahrokh F Shariat, Christian Bolenz, Pierre I Karakiewicz, et al.
Nature Reviews. Urology|March 28, 2023
Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic diseaseKyle M Rose, Heather L Huelster, Joshua J Meeks, et al.
European Urology Oncology|March 24, 2020
Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysisAshish M Kamat, Seth P Lerner, Michael O'Donnell, et al.
Pageof 30

Showing results (201-210 of 294) with videos related to

Sort By:
Pageof 30
BJU International|May 6, 2008
Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control studyJochen Walz, Shahrokh F Shariat, Nazareno Suardi, et al.
World Journal of Urology|September 9, 2016
Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)Francesco Soria, Shahrokh F Shariat, Seth P Lerner, et al.
The Journal of Urology|November 17, 2009
Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancerShahrokh F Shariat, Daher C Chade, Pierre I Karakiewicz, et al.
Journal of Oncology Practice|August 11, 2017
Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline SummarySam S Chang, Bernard H Bochner, Roger Chou, et al.
The Journal of Urology|May 1, 2017
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO GuidelineSam S Chang, Bernard H Bochner, Roger Chou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2022
Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative GroupsHeiko Schöder, Thomas A Hope, Michael Knopp, et al.
Future Oncology (London, England)|May 24, 2022
Targeting <i>FGFR3</i> alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trialSumanta K Pal, Diederik M Somford, Petros Grivas, et al.
BJU International|August 8, 2009
p53 expression in patients with advanced urothelial cancer of the urinary bladderShahrokh F Shariat, Christian Bolenz, Pierre I Karakiewicz, et al.
Nature Reviews. Urology|March 28, 2023
Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic diseaseKyle M Rose, Heather L Huelster, Joshua J Meeks, et al.
European Urology Oncology|March 24, 2020
Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysisAshish M Kamat, Seth P Lerner, Michael O'Donnell, et al.
Pageof 30